Face-to-face VAXPRED meeting summary – May 21–22, Copenhagen

On May 21–22, 2025, the VAXPRED team—Subtopic 1 of the Inno4Vac project—gathered in Lyngby, just outside Copenhagen, for a dynamic and productive face-to-face meeting. Hosted by the Technical University of Denmark (DTU), the event brought together VAXPRED members to review progress and align on next steps in this ambitious initiative.

July 2025

Accelerating vaccine development with AI

VAXPRED is a one of the 4 Subtopics of the Inno4Vac project, a collaborative European effort aimed at accelerating vaccine development and manufacturing. VAXPRED scope is working to build an open-access, cloud-based platform that uses artificial intelligence to predict vaccine efficacy and more likely to progress through later phases of vaccine development (https://www.inno4vac.eu/st1vaxpred).

Key Topics and progress

The meeting focused on several critical areas, with particular attention given to T-cell receptor (TCR) and B-cell receptor (BCR) profiling. Notably, strong advancements were reported in the project’s scientific objectives.

Inno4Vac Subtopic 1, VAXPRED, team members

A highlight of the meeting was the introduction of a novel denoising strategy, which significantly improves data quality by reducing noise while preserving essential signal features.

The meeting was also focused on the development of the VAXPRED platform itself. The team showcased substantial progress, including the successful integration of tools and standards from the Adaptive Immune Receptor Repertoire (AIRR) community. These integrations are essential for ensuring interoperability and data consistency across the platform.

Overall, the meeting highlighted substantial progress across all workstreams, with collaborative discussions and clear action points moving forward.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007799. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use made of the information contained therein.